Olema Pharmaceuticals Inc (NASDAQ:OLMA) has a beta value of 2.06 and has seen 1.79 million shares traded in the last trading session. The company, currently valued at $411.36M, closed the last trade at $6.02 per share which meant it lost -$0.14 on the day or -2.27% during that session. The OLMA stock price is -178.57% off its 52-week high price of $16.77 and 23.59% above the 52-week low of $4.60. If we look at the company’s 10-day average daily trading volume, we find that it stood at 1.19 million shares traded. The 3-month trading volume is 985.08K shares.
The consensus among analysts is that Olema Pharmaceuticals Inc (OLMA) is Buy stock at the moment, with a recommendation rating of 1.00. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 3 have rated it as a Hold, with 3 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is 0.17.
Olema Pharmaceuticals Inc (NASDAQ:OLMA) trade information
Sporting -2.27% in the red in last session, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the OLMA stock price touched $6.02 or saw a rise of 6.81%. Year-to-date, Olema Pharmaceuticals Inc shares have moved 3.26%, while the 5-day performance has seen it change 9.45%. Over the past 30 days, the shares of Olema Pharmaceuticals Inc (NASDAQ:OLMA) have changed -4.75%. Short interest in the company has seen 10.87 million shares shorted with days to cover at 8.38.
Wall Street analysts have a consensus price target for the stock at $27, which means that the shares’ value could jump 77.7% from current levels. The projected low price target is $27.0 while the price target rests at a high of $27.0. In that case, then, we find that the current price level is -348.5% off the targeted high while a plunge would see the stock gain -348.5% from current levels.
Olema Pharmaceuticals Inc (OLMA) estimates and forecasts
Figures show that Olema Pharmaceuticals Inc shares have underperformed across the wider relevant industry. The company’s shares have lost -60.99% over the past 6 months, with this year growth rate of -8.88%, compared to 16.40% for the industry. Revenue growth from the last financial year stood is estimated to be 0.00%.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -105.28% over the past 5 years. Earnings growth for 2025 is a modest -7.49% while over the next 5 years, the company’s earnings are expected to decrease by -13.34%.
OLMA Dividends
Olema Pharmaceuticals Inc is expected to release its next earnings report in February this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Olema Pharmaceuticals Inc (NASDAQ:OLMA)’s Major holders
Insiders own 3.21% of the company shares, while shares held by institutions stand at 85.86% with a share float percentage of 88.71%. Investors are also buoyed by the number of investors in a company, with Olema Pharmaceuticals Inc having a total of 195.0 institutions that hold shares in the company. The top two institutional holders are BVF INC/IL with over 9.14 million shares worth more than $98.85 million. As of 2024-06-30, BVF INC/IL held 16.2322% of shares outstanding.
The other major institutional holder is PARADIGM BIOCAPITAL ADVISORS LP, with the holding of over 7.9 million shares as of 2024-06-30. The firm’s total holdings are worth over $85.52 million and represent 14.0428% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF . As of Sep 30, 2024 , the former fund manager holds about 2.00% shares in the company for having 1.49 shares of worth $8.95 million while later fund manager owns 1.11 shares of worth $6.66 million as of Nov 30, 2024 , which makes it owner of about 1.49% of company’s outstanding stock.
